Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637428 | 0.88 | TSHR (0.55) | EPHX2CTSKCYP2C9HSD11B1TSHR | |
| SCHEMBL14417786 | 0.83 | ALDH1A1 (0.54) | EPHX2CTSKCYP2C9HSD11B1TSHR | |
| SCHEMBL17557665 | 0.82 | CTSK (0.50) | EPHX2CTSKCYP2C9HSD11B1GAA | |
| SCHEMBL31443321 | 0.82 | CTSK (0.52) | EPHX2CTSKCYP2C9HSD11B1GAA | |
| SCHEMBL17557565 | 0.82 | CTSK (0.47) | CTSKCYP2C9HSD11B1TSHRL3MBTL1 | |
| SCHEMBL30761942 | 0.81 | TSHR (0.48) | EPHX2CTSKCYP2C9HSD11B1TSHR | |
| SCHEMBL25123847 | 0.80 | CTSK (0.54) | EPHX2CTSKCYP2C9HSD11B1GAA | |
| SCHEMBL17591811 | 0.80 | CTSK (0.54) | EPHX2CTSKCYP2C9HSD11B1L3MBTL1 | |
| SCHEMBL19857415 | 0.80 | EPHX2 (0.58) | EPHX2TSHRL3MBTL1GAA | |
| SCHEMBL3841283 | 0.80 | CTSK (0.54) | EPHX2CTSKCYP2C9HSD11B1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324872-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324872-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | EPHX2 3664/4885CTSK 3314/4885CYP2C9 1172/4885 |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | EPHX2 3656/4885CTSK 3281/4885CYP2C9 1175/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | EPHX2 3664/4885CTSK 3314/4885CYP2C9 1172/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | EPHX2 3664/4885CTSK 3314/4885CYP2C9 1172/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | EPHX2 3664/4885CTSK 3314/4885CYP2C9 1172/4885 |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | EPHX2 3664/4885CTSK 3314/4885CYP2C9 1172/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | EPHX2 3664/4885CTSK 3314/4885CYP2C9 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.